Natco Pharma Shares Gain Focus Ahead of US Pomalidomide Capsules Launch

Natco Pharma Launches Pomalidomide Capsules in US Market

Natco Pharma, in partnership with Breckenridge Pharmaceutical, Inc., has launched Pomalidomide Capsules, a generic version of Pomalyst by Celgene, in the United States. The launch is a significant development for the company, further strengthening its oncology and specialty portfolio in the US.

Pomalidomide Capsules are indicated for the treatment of adult patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor, and have demonstrated disease progression on or within 60 days of completion of the last therapy. The drug is also approved for AIDS-related Kaposi sarcoma after failure of highly active antiretroviral therapy (HAART), as well as for HIV-negative adult patients with Kaposi sarcoma.

The product is available in 1 mg, 2 mg, 3 mg, and 4 mg strengths and is primarily distributed through specialty pharmacies and clinics.

Read also: Oshea Herbals Aims for Rs 650 Crore Revenue Amidst Expansion Efforts

Market Impact

The launch of Pomalidomide Capsules is expected to have a positive impact on Natco Pharma's share price. The company's stock has been trading at Rs 956.40 as of the previous trading session, down Rs 31.90 or 3.23 percent. The stock has touched a 52-week high of Rs 1,059.60 and a 52-week low of Rs 660.05 on 24 July, 2025 and 07 April, 2025, respectively.

Key Statistics

• Market capitalisation: Rs 17,130.07 crore
• 52-week high: Rs 1,059.60
• 52-week low: Rs 660.05
• Current stock price: Rs 956.40
• Daily price change: -Rs 31.90 or 3.23 percent

Read also: Suzlon to Expand Business Scope Beyond Wind Energy, Invests Rs 500 Crore in New Subsidiary This Fiscal Year